Literature DB >> 20363230

Determinants of BH3 binding specificity for Mcl-1 versus Bcl-xL.

Sanjib Dutta1, Stefano Gullá, T Scott Chen, Emiko Fire, Robert A Grant, Amy E Keating.   

Abstract

Interactions among Bcl-2 family proteins are important for regulating apoptosis. Prosurvival members of the family interact with proapoptotic BH3 (Bcl-2-homology-3)-only members, inhibiting execution of cell death through the mitochondrial pathway. Structurally, this interaction is mediated by binding of the alpha-helical BH3 region of the proapoptotic proteins to a conserved hydrophobic groove on the prosurvival proteins. Native BH3-only proteins exhibit selectivity in binding prosurvival members, as do small molecules that block these interactions. Understanding the sequence and structural basis of interaction specificity in this family is important, as it may allow the prediction of new Bcl-2 family associations and/or the design of new classes of selective inhibitors to serve as reagents or therapeutics. In this work, we used two complementary techniques--yeast surface display screening from combinatorial peptide libraries and SPOT peptide array analysis--to elucidate specificity determinants for binding to Bcl-x(L)versus Mcl-1, two prominent prosurvival proteins. We screened a randomized library and identified BH3 peptides that bound to either Mcl-1 or Bcl-x(L) selectively or to both with high affinity. The peptides competed with native ligands for binding into the conserved hydrophobic groove, as illustrated in detail by a crystal structure of a specific peptide bound to Mcl-1. Mcl-1-selective peptides from the screen were highly specific for binding Mcl-1 in preference to Bcl-x(L), Bcl-2, Bcl-w, and Bfl-1, whereas Bcl-x(L)-selective peptides showed some cross-interaction with related proteins Bcl-2 and Bcl-w. Mutational analyses using SPOT arrays revealed the effects of 170 point mutations made in the background of a peptide derived from the BH3 region of Bim, and a simple predictive model constructed using these data explained much of the specificity observed in our Mcl-1 versus Bcl-x(L) binders. (c) 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20363230      PMCID: PMC2896288          DOI: 10.1016/j.jmb.2010.03.058

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  44 in total

1.  Structural insights into the degradation of Mcl-1 induced by BH3 domains.

Authors:  Peter E Czabotar; Erinna F Lee; Mark F van Delft; Catherine L Day; Brian J Smith; David C S Huang; W Douglas Fairlie; Mark G Hinds; Peter M Colman
Journal:  Proc Natl Acad Sci U S A       Date:  2007-03-27       Impact factor: 11.205

2.  Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics.

Authors:  Anthony Letai; Michael C Bassik; Loren D Walensky; Mia D Sorcinelli; Solly Weiler; Stanley J Korsmeyer
Journal:  Cancer Cell       Date:  2002-09       Impact factor: 31.743

3.  Modeling backbone flexibility to achieve sequence diversity: the design of novel alpha-helical ligands for Bcl-xL.

Authors:  Xiaoran Fu; James R Apgar; Amy E Keating
Journal:  J Mol Biol       Date:  2007-05-05       Impact factor: 5.469

4.  Apoptosis initiated when BH3 ligands engage multiple Bcl-2 homologs, not Bax or Bak.

Authors:  Simon N Willis; Jamie I Fletcher; Thomas Kaufmann; Mark F van Delft; Lin Chen; Peter E Czabotar; Helen Ierino; Erinna F Lee; W Douglas Fairlie; Philippe Bouillet; Andreas Strasser; Ruth M Kluck; Jerry M Adams; David C S Huang
Journal:  Science       Date:  2007-02-09       Impact factor: 47.728

5.  Highly L and D enantioselective variants of horseradish peroxidase discovered by an ultrahigh-throughput selection method.

Authors:  Eugene Antipov; Art E Cho; K Dane Wittrup; Alexander M Klibanov
Journal:  Proc Natl Acad Sci U S A       Date:  2008-11-12       Impact factor: 11.205

6.  ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor.

Authors:  Christin Tse; Alexander R Shoemaker; Jessica Adickes; Mark G Anderson; Jun Chen; Sha Jin; Eric F Johnson; Kennan C Marsh; Michael J Mitten; Paul Nimmer; Lisa Roberts; Stephen K Tahir; Yu Xiao; Xiufen Yang; Haichao Zhang; Stephen Fesik; Saul H Rosenberg; Steven W Elmore
Journal:  Cancer Res       Date:  2008-05-01       Impact factor: 12.701

7.  Yeast surface display for directed evolution of protein expression, affinity, and stability.

Authors:  E T Boder; K D Wittrup
Journal:  Methods Enzymol       Date:  2000       Impact factor: 1.600

8.  Development of a high-throughput fluorescence polarization assay for Bcl-x(L).

Authors:  Haichao Zhang; Paul Nimmer; Saul H Rosenberg; Shi-Chung Ng; Mary Joseph
Journal:  Anal Biochem       Date:  2002-08-01       Impact factor: 3.365

9.  Hydrophile scanning as a complement to alanine scanning for exploring and manipulating protein-protein recognition: application to the Bim BH3 domain.

Authors:  Melissa D Boersma; Jack D Sadowsky; York A Tomita; Samuel H Gellman
Journal:  Protein Sci       Date:  2008-05-08       Impact factor: 6.725

10.  Phaser crystallographic software.

Authors:  Airlie J McCoy; Ralf W Grosse-Kunstleve; Paul D Adams; Martyn D Winn; Laurent C Storoni; Randy J Read
Journal:  J Appl Crystallogr       Date:  2007-07-13       Impact factor: 3.304

View more
  52 in total

1.  Identification of a novel Mcl-1 protein binding motif.

Authors:  William J Placzek; Mattia Sturlese; Bainan Wu; Jason F Cellitti; Jun Wei; Maurizio Pellecchia
Journal:  J Biol Chem       Date:  2011-09-27       Impact factor: 5.157

Review 2.  Protein binding specificity versus promiscuity.

Authors:  Gideon Schreiber; Amy E Keating
Journal:  Curr Opin Struct Biol       Date:  2010-11-09       Impact factor: 6.809

3.  Biophysical basis of the promiscuous binding of B-cell lymphoma protein 2 apoptotic repressor to BH3 ligands.

Authors:  Vikas Bhat; Max B Olenick; Brett J Schuchardt; David C Mikles; Caleb B McDonald; Amjad Farooq
Journal:  J Mol Recognit       Date:  2013-10       Impact factor: 2.137

Review 4.  Designing specific protein-protein interactions using computation, experimental library screening, or integrated methods.

Authors:  T Scott Chen; Amy E Keating
Journal:  Protein Sci       Date:  2012-06-08       Impact factor: 6.725

5.  Locating Herpesvirus Bcl-2 Homologs in the Specificity Landscape of Anti-Apoptotic Bcl-2 Proteins.

Authors:  Glenna Wink Foight; Amy E Keating
Journal:  J Mol Biol       Date:  2015-05-23       Impact factor: 5.469

6.  Design, synthesis and evaluation of marinopyrrole derivatives as selective inhibitors of Mcl-1 binding to pro-apoptotic Bim and dual Mcl-1/Bcl-xL inhibitors.

Authors:  Chunwei Cheng; Maria E Balasis; Yan Liu; Thomas P Garner; Rongshi Li; Kenyon G Daniel; Jerry Li; Yong Qin; Evripidis Gavathiotis; Said M Sebti
Journal:  Eur J Med Chem       Date:  2014-11-20       Impact factor: 6.514

7.  Peptide design by optimization on a data-parameterized protein interaction landscape.

Authors:  Justin M Jenson; Vincent Xue; Lindsey Stretz; Tirtha Mandal; Lothar Luther Reich; Amy E Keating
Journal:  Proc Natl Acad Sci U S A       Date:  2018-10-15       Impact factor: 11.205

8.  Identification of the β-lactamase inhibitor protein-II (BLIP-II) interface residues essential for binding affinity and specificity for class A β-lactamases.

Authors:  Nicholas G Brown; Dar-Chone Chow; Kevin E Ruprecht; Timothy Palzkill
Journal:  J Biol Chem       Date:  2013-04-27       Impact factor: 5.157

9.  Molecular determinants of the binding specificity of BH3 ligands to BclXL apoptotic repressor.

Authors:  Vikas Bhat; Max B Olenick; Brett J Schuchardt; David C Mikles; Caleb B McDonald; Amjad Farooq
Journal:  Biopolymers       Date:  2014-06       Impact factor: 2.505

10.  Engineering Specificity from Broad to Narrow: Design of a β-Lactamase Inhibitory Protein (BLIP) Variant That Exclusively Binds and Detects KPC β-Lactamase.

Authors:  Dar-Chone Chow; Kacie Rice; Wanzhi Huang; Robert L Atmar; Timothy Palzkill
Journal:  ACS Infect Dis       Date:  2016-10-26       Impact factor: 5.084

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.